Prevalence of Drug-Related Emergency Department Visits at a Teaching Hospital in Malaysia by unknown
ORIGINAL RESEARCH ARTICLE
Prevalence of Drug-Related Emergency Department Visits
at a Teaching Hospital in Malaysia
Abubakar Ibrahim Jatau1 • Myat Moe Thwe Aung2 •
Tuan Hairulnizam Tuan Kamauzaman3 • Ab Fatah Ab Rahman1
Published online: 23 October 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Background Data on the prevalence of adverse drug
event (ADE)-related emergency department (ED) visits in
developing countries are limited. Malaysia is located in
South-East Asia, and, to our knowledge, no information
exists on ADE-related ED visits.
Objective The objective of this study was to determine
the prevalence, preventability, severity, and outcome of
drug-related ED visits.
Methodology A cross-sectional study was conducted in
consenting patients who visited the ED of Hospital
Universiti Sains Malaysia over a 6-week period. The ED
physician on duty determined whether or not the visit was
drug related according to set criteria. Other relevant
information was extracted from the patient’s medical folder
by a clinical pharmacist.
Results Of the 434 consenting patients, 133 (30.6 %; 95 %
confidence interval [CI] 26–35 %) visits were determined to
be ADE related; 55.5 % were considered preventable,
11.3 % possibly preventable, and 33.1 % not preventable.
Severity was classed as mild in 1.5 %, moderate in 67.7 %,
and severe in 30.8 %. The most common ADEs reported
were drug therapeutic failure (55.6 %) and adverse drug
reactions (32.3 %). The most frequently implicated drugs
were antidiabetics (n = 31; 23.3 %), antihypertensives
(n = 28; 21.1 %), antibiotics (n = 13; 9.8 %), and anti-
asthmatics (n = 11; 8.3 %). A total of 93 patients (69.9 %)
were admitted to the ED for observation, 25 (18.8 %) were
discharged immediately after consultation, and 15 (11.3 %)
were admitted to the ward through the ED.
Conclusion The prevalence of ADE-related ED visits was
high; more than one-half of the events were considered
preventable and one-third was classed as severe. As such,
preventive measures will minimize future occurrences and
increase patient safety.
Key Points
Three in ten patients seeking care at the emergency
department of a teaching hospital in Malaysia were
for events associated with drug use.
Drug therapeutic failure due to medication non-
adherence was the most commonly reported adverse
drug event.
1 Introduction
An adverse drug event (ADE) is ‘‘any untoward medical
occurrence in a patient or clinical investigation subject
administered a pharmaceutical product and which does not
necessarily have to have a causal relationship with this
treatment’’ [1]. ADEs have been identified as a major public
health concern and are responsible for a high level of mor-
bidity and mortality worldwide [2]. In the USA, ADEs
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accounted for 17 million emergency department (ED) visits
and 8.7 million hospital admissions annually [3]. ADEs
occur in all clinical settings and are responsible for
0.77–37.6 % of ED visits [4–6]. They also contributed to an
increase in healthcare cost, loss of productivity, increased
hospital stay and time away from work, as well as lower
patient satisfaction [7–9]. In Canada, ADEs were responsible
for a total annual cost of $Can35.7 million in 2008 [10].
In Malaysia, over 2 million hospital admissions and 19
million outpatient visits were documented in government
hospitals in 2014 [11]. Similarly, over 8 million and 33
million prescriptions were dispensed to in-patients and out-
patients, respectively [12]. Despite these figures, data on
the prevalence of ADE-related hospitalizations in Malaysia
are still scarce. Thus, it is necessary to identify the burden
of ADEs in an ED to better understand the challenges faced
by healthcare professionals in Malaysia.
Many of the previous studies on ADE-related hospital-
izations focused on patients in ambulatory care units and
those admitted to hospital wards, with relatively few
evaluating the number of patients seeking care in the ED
[13]. The aim of this study was to determine the prevalence
of ADE-related ED visits at a teaching hospital in Malay-
sia. Our secondary objective was to determine the degree
of severity, preventability, and outcome of these visits.
2 Methods
2.1 Settings
The study was conducted at the ED of Hospital Universiti
Sains Malaysia (HUSM), Kelantan, Malaysia. HUSM is a
767-bed tertiary hospital and was considered the largest
referral centre in the east coast of Malaysia [14]. The ED
receives approximately 65,000 patients per annum.
2.2 Patients
All patients coming to the HUSM ED during the period
December 2014 to January 2015 were considered for this
study. The exclusion criteria were (1) patients referred
from another hospital, (2) patients on a scheduled visit to
the ED, and (3) patients with medico-legal cases. The
remainder of the patients was approached for consent. Only
those who consented to participate were interviewed.
Recruitment was halted when the required minimum
number of patients was reached.
2.3 Design
A cross-sectional study was performed over a 6-week period.
Patient interviews were conducted between 09:00 am and
05:00 pm, Sunday to Thursday. The ED physician determined
whether or not the chief presenting complaints were related to
drugs, based on the following criteria [15]: (1) known drug
actions as described in drug monographs and/or literature, (2)
the temporal relationship between the event and the time of
drug use, and (3) the nature of the current underlying dis-
ease(s). Information regarding the patient’s socio-demo-
graphic characteristics, current drug use, current use of any
modality of complementary and alternative medicine (CAM),
and history of visiting multiple prescribers or pharmacies in
the last 14 days were collected. Patient medical and medica-
tion history, drug allergy, history of presenting illness, recent
hospital admission, drugs dispensed at the ED, and outcome of
the visits was also obtained. The categorization of the ADE,
preventability, severity, and outcome of the visits were
determined based on definitions adopted and modified from
previous studies, as described in Sect. 2.4.
2.4 Definitions
An ED visit was considered ADE related when the chief
presenting complaint was related to drug use [8]. If the patient
had other symptoms related to drug use, and the chief pre-
senting complaint was not related to these, the ED visit was
considered not ADE related. ADE-related ED visits were
classified into the following five categories. (1) Adverse drug
reaction (ADR)—a ‘‘response to a drug that is noxious or
unintended, and that occurs at doses normally used for the
prophylaxis, diagnosis, or therapy of disease’’ [9]. (2) Drug
therapeutic failure (DTF)—an absence of therapeutic
response (deterioration of disease state or condition) to a drug
that could be linked causally either to a prescribed dose that
was too low, medication non-adherence, recent dose reduction
and interaction, or inadequate monitoring [16]. The visit was
regarded as due to DTF when caused by medication non-
adherence where the patient’s drug-taking behavior did not
correspond with agreed recommendations from the healthcare
provider, resulting in a disease or condition not stabilizing or
symptoms worsening [17]. (3) Accidental drug overdose—
unintentional administration of a drug (set at an amount higher
than the normal recommended therapeutic dose, that has the
potential to cause harm, e.g., a young child or an adult with
impaired mental abilities swallowing medication left within
their grasp or an adult mistakenly taking an incorrect drug or
dose) [3]. (4) Intentional drug overdose—deliberate admin-
istration of a drug at an amount higher than the normal rec-
ommended dose, that has the potential to cause harm (e.g., for
the purpose of self-harm, suicide attempts, or to achieve
euphoric state) [3]. (5) Untreated indication—when the chief
presenting complaint is related to a disease or condition that
requires a drug therapy and the patient did not seek or receive
such therapy (possibly due to mental illness or ignorance of
the disease condition) [3].
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Preventability was evaluated based on three categories
[18]: (1) Preventable—the drug-related ED visit was the
result of misuse of a drug, inappropriate discontinuation of
treatment, non-adherence, or self-medication; (2) Possibly
preventable—the visit was due to failure to monitor drug
therapy or an error in prescribing, dispensing, or adminis-
tration; or (3) Not preventable—the ADE occurred during
compliance with good drug utilization.
The severity of drug-related ED visits was classified
according to the following criteria [19]: (1) Mild—a lab-
oratory abnormality or the symptom did not require drug
intervention, (2) Moderate—a laboratory abnormality or
symptom that required drug intervention at the ED, (3)
Severe—the symptom required hospital admission, was
life-threatening, or resulted in permanent disability.
The outcome of the drug-related ED visit was categorized
into three groups: (1) discharged immediately after consulta-
tion with the ED physician, (2) admitted to the ED-observa-
tion ward for a maximum of 72 h, and (3) admitted to a
hospital ward through the ED. Drug classification was per-
formed according to MIMS.com Malaysia version 1.3.0 [20].
2.5 Sample Size Calculation
The sample size was calculated using a single proportion
formula [21], adopting 38.0 % as the expected proportion
of population with ADE-related ED visits, as per previous
literature [22]; a 0.05 significance (alpha) level at a 95 %
confidence interval (CI); and taking into consideration the
20 % of included patients who would leave without seeing
a physician. A sample size of 434 was calculated.
2.6 Statistical Analysis
Data were analyzed using statistical software (SPSS ver-
sion 21, SPSS Inc., Chicago, IL, USA). The prevalence of
ADE-related ED visits was calculated by dividing the
number of patients with ADE-related ED visits by the total
sample size. Descriptive analysis of socio-demographic,
clinical, and drug-related variables was conducted. Results
were presented as frequency (percentage) for categorical
variables and mean (standard deviation [SD]) for numerical
variables. The Chi squared goodness-of-fit test was used to
determine the distribution of cases in a single categorical
variable at a 0.05 significance (alpha) level.
3 Results
There was a total of 7530 ED visits over the 6-week period;
3573 patients came to the ED between 09:00 am and
05:00 pm Sunday to Thursday. Of the 1162 patients
selected for the study, 728 were excluded, for the following
reasons: referral from other hospital (n = 714); scheduled
visit (n = 8); declined to participate (n = 4); and medico-
legal cases (n = 2). Therefore, 434 eligible patients were
interviewed. The number of ED physician-identified ADE-
related ED visits was 133 (30.6 %; 95 % CI 26–35 %).
Table 1 illustrates the characteristics of the patients with an
ADE-related ED visit. The mean (SD) age of the patients
with an ADE-related ED visit was 41.0 (21.58) years. Of
the 133 patients, 62 % were female and 96.0 % were of
Malay ethnicity. The proportion of patients with formal
education was 66.9 %, and 70 % of participants were
married. A total of 110 patients (82.7 %) were currently
taking medications at the time of the ED visit; 17 (12.8 %)
claimed use of one or more different modalities of CAM.
The most commonly reported chronic diseases among
patients with an ADE-related visit were diabetes mellitus
(DM) (n = 55; 41.4 %); hypertension (n = 54; 40.6 %);
and asthma (n = 13; 9.7 %) (A person could have more
than one chronic disease).
Five categories of ADE were reported: (1) DTF
(n = 74; 55.6 %), (2) ADR (n = 43; 32.3 %), (3) acci-
dental drug overdose (n = 7; 5.2 %), (4) intentional drug
overdose (n = 6; 4.5 %), and (5) untreated indication
(n = 3; 3.2 %). Female patients dominated in most of the
ADE categories. The prevalence of DTF, ADR, and acci-
dental overdose was higher among the elderly population
(C60 years). Medication non-adherence was found to be
the major cause of DTF (81.1 %). Table 2 demonstrates
the prevalence of different categories of ADE among sex
and age categories.
Of the 133 ADE-related ED visits, 74 (55.6 %) were
considered preventable, with DTF due to medication non-
adherence accounting for 85.3 %. A total of 41 (30.8 %) of
ADE-related ED visits were classed as severe, with DTF
due to medication non-adherence responsible for 41.5 % of
this level of severity. There was no report of permanent
disability or death from these visits. Of the subjects, 25
(18.8 %) were discharged immediately after consultation
with the ED physician, 93 (69.9 %) were admitted to the
ED-observation ward for a maximum of 72 h, and 15
(11.3 %) were admitted to a hospital ward from the ED.
Admission to the ED-observation ward was mainly due to
hypoglycemia secondary to antidiabetic therapy (n = 10;
10.8 %), uncontrolled DM (n = 10; 10.8 %), and hyper-
tensive urgency (n = 9; 9.7 %). Admission to the hospital
ward was mostly due to uncontrolled DM (n = 2; 13.3 %).
A total of 45 individual drugs and 18 drug combinations
were involved in the 133 ADE-related ED visits. The most
frequently implicated drugs were antidiabetics (n = 31;
23.3 %), antihypertensives (n = 28; 21.1 %), antibiotics
(n = 13; 9.8 %), anti-asthmatics (n = 11; 8.3 %), and
diuretics (n = 8; 6.0 %). The most frequent single drugs
reported were insulin (n = 13; 9.8 %), furosemide (n = 7;
Drug-Related ED Visits in Malaysia 389
2.3 %), salbutamol (n = 6; 4.5 %), and gliclazide (n = 5;
3.8 %). The drug combinations most involved were
amoxicillin ? clavulanic acid (n = 4; 3.0 %) and
rifampicin ? isoniazid (n = 3; 2.3 %).
The most common complaints among patients with ADE-
related ED visits were fatigue, irritability, sweating, uncon-
sciousness, hypertension, skin reactions, upper gastroin-
testinal bleeding, palpitations, giddiness, shortness of breath,
tarry stools, abnormal behavior, chest pain, convulsions,
lethargy, edema, and Stevens–Johnson Syndrome (SJS).
4 Discussion
To our knowledge, this is the first study to determine the
prevalence of ADE-related ED visits at a teaching hospital
in Malaysia. A prevalence of 30.6 % (95 % CI 26–35) for
ADE-related ED visits was determined within the 6-week
period. More than one-half of the ADEs were determined
to have been preventable, and almost one-third had a
severe outcome. The prevalence rate found in the current
study is consistent with results of previous studies
Table 1 Demographic
characteristics of cases with
adverse drug event-related
emergency department visit
Patient characteristics Mean age (SD) Frequency (%), n = 133 P valuea
Age (years)








Male 44.45 (21.14) 50 (38.0) 0.015
Female 51.35 (16.50) 83 (62.0)
Marital status




Malay 128 (96.0) 0.438
Chinese 5 (4.0)
Education status
None 44 (33.1) 0.001
Yes 89 (66.9)





Possibly preventable 15 (11.3)





Outcome of the visit
Discharged immediately 25 (18.8)
Admitted to ED 93 (69.9)
Admitted to the ward 15 (11.3)
ED emergency department, SD standard deviation
a Chi square goodness of fit
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conducted in Spain and the USA using a similar study
design and population (28.1–33.2 %) [23–26]. In contrast,
the prevalence rate was higher than in other studies per-
formed in England, Finland, Canada, and Taiwan, which
were in the range of 0.77–4.0 % [24, 27–30]. In the current
study, the rate of ADE-related admissions to the ward
through the ED was 11.3 %, which is similar to rates found
in a study conducted in Malaysia (12.7 %) [31]. The high
prevalence rate found in this study may be due to a broader
definition of ADE, eligibility criteria, and study population
used. This was adopted to ensure a comprehensive
knowledge of ADE-related hospitalization. Moreover, the
high proportion of patients with DTF may also be
responsible for the high prevalence rate.
In the current study, the proportion of female patients
found to be associated with ADE-related ED visits and
currently receiving medications was higher than that of
male patients. This was in agreement with previous studies
[27, 32, 33]. The female sex has been identified as a risk
factor associated with ADE-related ED visits [23, 25, 34,
35]. This is possibly due to the increased bioavailability of
drugs, greater sensitivity of female target organs to drugs,
and polypharmacy due to gender-specific treatments [36].
ADE-related complaints at the ED in the current study
were higher among the elderly. This was consistent with
findings of previous studies [4, 7, 24, 37]. This could
possibly be because the body’s ability to handle drugs
diminishes with age, leading to changes in drug pharma-
cokinetics, altered organ responses, and homeostatic
counter-regulation to drug effects [38]. More patients
without formal education had ADE-related ED visits than
patients with higher education. Similar studies have shown
that patients with a higher level of education have a better
perception of the risks of ADEs [39]. A higher level of
education brings a greater conscious awareness of the risks
associated with drug use. Many previous studies on
prevalence of ADEs did not evaluate marital status [13].
However, our study reveals a significant difference in ADE
occurrence within married, divorced, and single patients,
with a married population having a higher percentage of
patients with ADE-related ED visits. Similarly, Chri-
schilles et al. [40, 41] and Hema et al. [40, 41] also found
that a higher proportion of patients with ADE were mar-
ried. An explanation for this within the current study may
be that over 40 % of the patients with ADEs were elderly
and more than one-half were females, who were earlier
found to have a higher incidence of ADE-related
hospitalization.
The ADE category with the highest prevalence rate in
the current study was DTF, which accounted for more than
one-half of ADE-related ED visits. This is consistent with a
similar study conducted in a hospital ward in Malaysia
[22]. In the current study, medication non-adherence was
the major cause of DTF-related ED visits. The prevalence
rate of DTF due to medication non-adherence reported was
higher than that found in previous studies [8, 15, 42–44].
This variation may be due to more patients with chronic
diseases visiting our ED with ADE-related complaints.
However, patients with underlying chronic illness were
found to have a higher chance of medication non-adher-
ence [43]. Another reason for the higher prevalence rate of
DTF due to medication non-adherence may be associated
Table 2 Categories of adverse drug events among sex and age categories
Categories of adverse drug event, n (%)a P valueb
DTF ADR Accidental drug overdose Intentional drug overdose Untreated indication
Sex
Male 30 (40.5) 12 (27.9) 4 (57.1) 4 (66.7) 0 (0.0) 0.160
Female 44 (59.5) 31 (72.1) 3 (42.1) 2 (33.3) 3 (100)
Age category (years)
B9 3 (1.6) 0 (0.0) 1 (14.3) 0 (0.0) 0 (0.0) \0.001
10–19 1 (0.0) 2 (4.7) 1 (14.3) 0 (0.0) 1 (33.3)
20–29 6 (9.5) 8 (18.6) 0 (0.0) 3 (50.0) 0 (0.0)
30–39 8 (11.1) 5 (11.6) 0 (0.0) 1 (16.7) 2 (66.7)
40–49 7 (9.5) 8 (18.6) 1 (14.3) 2 (33.3) 0 (0.0)
50–59 22 (31.7) 5 (11.6) 1 (14.3) 0 (0.0) 0 (0.0)
C60 27 (36.5) 15 (34.9) 3 (42.9) 0 (0.0) 0 (0.0)
Prevalencec 17.0 9.9 1.6 1.4 0.7
ADR adverse drug reaction, DTF drug therapeutic failure
a Frequency is calculated as the number of cases in 133 patients with adverse drug event-related emergency department visits
b Chi squared goodness of fit
c Prevalence is calculated as the percentage of cases with adverse drug events in the sample size (434)
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with the busy and overcrowded nature of some public
hospitals in Malaysia, which may not allow adequate
patient counseling, especially regarding medication
adherence [45, 46]. Medication non-adherence has become
a silent burden of healthcare [39, 44, 47]; thus, many
intervention measures have been made to improve adher-
ence to increase patient safety. Such interventions include
patient education via verbal and written instructions,
illustrations, and audiovisuals by healthcare providers, and
reminders such as medication calendars, medication
schedule alerts, stickers, box alarms, and pill timers. In
Malaysia, efforts have been made to improve medication
adherence, including the use of short message alerts, called
MySMS, in some hospitals [48] and the establishment of
Medication Therapy Adherence Clinic (MTAC) services
operated by pharmacists in some public hospitals. These
services have resulted in significant improvements in
medication adherence [49]. Studies have shown that
pharmacist interventions have played a major role in
improving medication adherence, especially among
patients with chronic illness. The pharmacist is an expert
on drugs and has the skills and expertise to improve
medication adherence and potentially minimize the
prevalence of DTF-related ED visits [50, 51]. More inter-
vention measures are needed to improve medication
adherence.
In the current study, ADRs account for one-third of the
ADE-related ED visits. This rate is consistent with similar
studies conducted in India [52] and in hospital wards in
Malaysia and Germany [33, 38]. Hypoglycemia was the
most common complaint associated with ADRs, mainly
related to antidiabetic therapy (gliclazide and insulin). The
high rate of ADRs in the current study may be explained by
the poor ADR monitoring and reporting system in
Malaysia. Despite the establishment of the Malaysian
Adverse Drug Reaction Advisory Committee (MADRAC)
in 1987 to receive and monitor ADR reporting, the
response is still very low compared with other countries
[53]. Reports have identified some of the factors associated
with under-reporting of ADRs in Malaysia, including (1)
lack of awareness on the importance of and the need for
ADR monitoring and reporting, (2) uncertainty about
whether or not the event was an ADR, (3) opinion that the
reaction was too trivial or well known to report, (4) lack of
knowledge on how to report, and (5) inadequate time for
reporting [54]. If ADRs are not reported, then, predictably,
the extent of the occurrence, the people at risk, and the
drugs involved will not be well known. As such, preventive
interventions will be hampered, leading to increasing
numbers of ADRs. Another reason for the high ADR
prevalence rate in our study may be related to the current
treatment guidelines for DM and the poor glycemic control
associated with oral antidiabetic drugs. In Malaysia,
prevalence of DM is high, at 20 % [55, 56], and the
majority of patients have experienced sub-optimal gly-
cemic control with oral hypoglycemic drugs. Thus, early
insulin therapy has been included in the current treatment
guidelines for DM, and this has led to increased levels of
insulin use [57, 58]. However, this may be responsible for
the high prevalence of ADRs related to insulin-induced
hypoglycemia in the current study. Healthcare providers
should therefore discuss and monitor insulin therapy with
their patient, with regards to possible ADRs and how to
manage hypoglycemia associated with the therapy.
More than one-half of the ADEs identified were pre-
ventable, with over 80 % contributed by DTF and 50 % by
females. This is similar to results found in Saudi Arabia
and Canada [12, 19, 59]. These findings signal the possi-
bility of preventing more ADEs by improving medication
adherence and minimizing other preventable ADEs iden-
tified. Healthcare professionals and policy makers should
therefore focus their attention, efforts, and resources to the
identified preventable ADEs to improve patient safety [60].
In the current study, almost one-third and two-thirds of
the ADE-related ED visits were severe and moderately
severe, respectively; this is similar to findings in other
studies [26, 61]. A high proportion of females experienced
severe outcomes from ADEs due to ADRs and DTF, which
is also consistent with previous studies [42, 62]. These
findings have shown the healthcare challenges posed by
DTF and ADRs, and hence, the urgent need for interven-
tions to prevent further occurrences. There were no reports
of death or permanent disability within the current study,
although two patients presented with SJS, involving oral
cloxacillin and a topical skincare cream containing colla-
gen (Dnarz). This is similar to a retrospective cohort
study among patients of Asian descent, which found
cloxacillin to be among the drugs causing SJS [63]. The
pathogenesis of SJS was believed to be due to genetic
susceptibility, therefore, more pharmacogenomics studies
are needed to determine the drugs and groups of people at
high risk of SJS [63].
In the current study, more than two-thirds of the cases
were admitted to the ED-observation ward and experienced
more severe ADEs. Most presented with hypoglycemic and
hypertensive symptoms associated with anti-diabetic and
antihypertensive use. Therefore, a need exists for a clinical
pharmacist in the ED, for adequate detection, reporting,
and preventing of ADEs. Pharmacists, as drug experts,
specialize in recognizing ADEs in all clinical settings.
Consequently, most physicians lack adequate knowledge
and expertise to detect and report ADEs, and it has been
reported that over 40 % of ADEs presented at EDs were
misdiagnosed by ED physicians [64].
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The classes of drug most frequently implicated were
anti-diabetics, cardiovascular system agents, central ner-
vous system agents, antibiotics, anti-asthmatics, and
diuretics, similar to findings from other studies [15, 61, 65–
68]. This may be associated with the higher number of
patients with chronic illness reported in the study. Insulin,
furosemide, salbutamol, gliclazide, and amlodipine were
the most commonly reported drugs. Similar studies have
shown that these drugs have been associated with an
increased likelihood of ADE-related ED visits [50, 69, 70].
Amphetamine was commonly associated with intentional
drug overdose among male patients. This indicates a need
for close monitoring and patient counseling when pre-
scribing and dispensing such drugs given their potential to
cause ADEs leading to ED visits.
Limitations of this study include that it was limited to
one hospital, and the findings may not be generalized to a
larger population in Malaysia. In addition, the study period,
sample, and lack of internal validation of ADEs could
further affect the results reported.
5 Conclusion
The prevalence of ADE-related ED visits in Malaysia is
high. More than one-half of these visits were pre-
ventable and due to DTF. Medication non-adherence was
the major cause of DTF and was responsible for the high
percentage of severe ADEs admitted to the ED-observation
ward. This indicates the need for an effective intervention
strategy, such as patient education on drug utilization,
engaging the services of a clinical pharmacist at the ED,
and other measures targeted at preventable ADEs to
improve patient safety.
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